In:
Clinical Management Issues, Seed SRL, Vol. 6, No. 2 ( 2012-06-15), p. 43-50
Abstract:
Gliomatosis cerebri is a rare diffuse glioma with a growth pattern consisting of exceptionally extensive infiltration of the CNS with involvement of at least three lobes. It may appear de novo (primary gliomatosis) or result from the spreading of a focal glioma (secondary gliomatosis). Bevacizumab is a monoclonal antibody anti-VEGF active against recurrent high grade gliomas after standard therapy. We report the case of a 41-year-old man with a secondary gliomatosis treated with bevacizumab and temozolomide who responded and the response lasted 17 months. Moreover, we focus on the side effects (hypertension, deep vein thrombosis) induced by bevacizumab and their effective treatments.
Type of Medium:
Online Resource
ISSN:
2283-3137
,
1973-4832
DOI:
10.7175/cmi.v6i2.624
Language:
Unknown
Publisher:
Seed SRL
Publication Date:
2012
detail.hit.zdb_id:
2744441-7
